Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation

Journal of Clinical Pathology

Volumn 64, Issue 11, 2011, Pages 1010-1013

  Barrio, S ^a   Gallardo, M ^a   Albizua, E ^a,b   Jimenez, A ^a   Rapado, I ^a   Ayala, R ^a,c   Gilsanz, F ^a,c   Martin Subero, J I ^d   Martinez Lopez, J ^a,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA METHYLATION; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; ZNF577 GENE;

ADULT; AGED; DNA METHYLATION; DNA, NEOPLASM; DNA-BINDING PROTEINS; EPIGENOMICS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; POLYCYTHEMIA VERA; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; THROMBOCYTHEMIA, ESSENTIAL; TRANSCRIPTION FACTORS;

EID: 80054909843     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200175     Document Type: Article

References (21)

1. Martin-Subero JI, Ammerpohl O, Bibikova M, et al. A comprehensive microarraybased DNA methylation study of 367 hematological neoplasms. PLoS One 2009;4: e6986.
2. Gotze K, Platzbecker U, Giagounidis A, et al. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol 2009;89:841-50.
3. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-97. (Pubitemid 47281402)
4. Ugo V, James C, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Med Sci (Paris) 2005;21:669-70. (Pubitemid 40979241)
5. Albizua E, Gallardo M, Barrio S, et al. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. Ann Hematol 2011;90:939-46.
6. Goldman JM, Green AR, Holyoake T, et al. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 2009;23:1708-15.
7. Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008;22:740-47. (Pubitemid 351552623)
8. Mithraprabhu S, Grigoriadis G, Khong T, et al. Deactylase inhibition in myeloproliferative neoplasms. Invest New Drugs 2010;28(Suppl 1):S50-7.
9. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-55.
10. Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008;123:1586-92.
11. Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 2008;26:1920-30.
12. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010;91:174-9.
13. Rapado I, Grande S, Albizua E, et al. High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 2009;11:155e61.
14. Rapado I, Albizua E, Ayala R, et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol 2008;87:741-9.
15. Bibikova M, Le J, Barnes B, et al. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 2009;1:117-200.
16. Martin-Subero JI, Kreuz M, Bibikova M, et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009;113:2488-97.
17. Chim CS, Wan TS, Fung TK, et al. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol 2010;63:942-6.
18. Chim CS, Fung TK, Liang R. Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential thrombocythaemia. J Clin Pathol 2010;63:518-21.
19. Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 2009;30:592-602.
20. Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008;93:1635-44.
21. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009;458:97-101.